CN112955471A - Cd3抗体及其药物用途 - Google Patents

Cd3抗体及其药物用途 Download PDF

Info

Publication number
CN112955471A
CN112955471A CN201980072290.1A CN201980072290A CN112955471A CN 112955471 A CN112955471 A CN 112955471A CN 201980072290 A CN201980072290 A CN 201980072290A CN 112955471 A CN112955471 A CN 112955471A
Authority
CN
China
Prior art keywords
antibody
antigen
brc
cells
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980072290.1A
Other languages
English (en)
Other versions
CN112955471B (zh
Inventor
应华
张玲
杨筱莹
葛虎
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN202211304269.XA priority Critical patent/CN116396386A/zh
Publication of CN112955471A publication Critical patent/CN112955471A/zh
Application granted granted Critical
Publication of CN112955471B publication Critical patent/CN112955471B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

本公开涉及CD3抗体及其药物用途。具体涉及CD3抗体分子与其他靶点的结合分子形成多特异性抗体。多特异性抗体能够同时与CD3和其他肿瘤相关抗原相结合，结合肿瘤相关抗原表达细胞的同时，结合并激活CD3阳性的T细胞，进而促进T细胞对表达肿瘤相关抗原的肿瘤细胞特异性的杀伤。同时，本公开还提供多特异性抗体的制备、应用。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201980072290.1A 2018-12-07 2019-12-06 Cd3抗体及其药物用途 Active CN112955471B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211304269.XA CN116396386A (zh) 2018-12-07 2019-12-06 Cd3抗体及其药物用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018114917813 2018-12-07
CN201811491781 2018-12-07
PCT/CN2019/123548 WO2020114478A1 (zh) 2018-12-07 2019-12-06 Cd3抗体及其药物用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211304269.XA Division CN116396386A (zh) 2018-12-07 2019-12-06 Cd3抗体及其药物用途

Publications (2)

Publication Number Publication Date
CN112955471A true CN112955471A (zh) 2021-06-11
CN112955471B CN112955471B (zh) 2022-11-22

Family

ID=70975360

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211304269.XA Pending CN116396386A (zh) 2018-12-07 2019-12-06 Cd3抗体及其药物用途
CN201980072290.1A Active CN112955471B (zh) 2018-12-07 2019-12-06 Cd3抗体及其药物用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211304269.XA Pending CN116396386A (zh) 2018-12-07 2019-12-06 Cd3抗体及其药物用途

Country Status (12)

Country Link
US (1) US20220242953A1 (zh)
EP (1) EP3892639A4 (zh)
JP (1) JP7461950B2 (zh)
KR (1) KR20210100654A (zh)
CN (2) CN116396386A (zh)
AU (1) AU2019394241A1 (zh)
BR (1) BR112021010026A2 (zh)
CA (1) CA3121565A1 (zh)
MX (1) MX2021006389A (zh)
TW (1) TWI821474B (zh)
WO (1) WO2020114478A1 (zh)
ZA (1) ZA202104518B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023138551A1 (zh) * 2022-01-20 2023-07-27 上海君实生物医药科技股份有限公司 抗cd3和抗cd20双特异性抗体及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023284806A1 (zh) * 2021-07-14 2023-01-19 江苏恒瑞医药股份有限公司 特异性结合cd38、bcma和cd3的抗原结合分子及其医药用途
WO2023029089A1 (zh) * 2021-09-03 2023-03-09 苏州近岸蛋白质科技股份有限公司 抗cd3人源化抗体
WO2023174238A1 (zh) * 2022-03-14 2023-09-21 江苏恒瑞医药股份有限公司 特异性结合gprc5d和cd3的抗原结合分子及其医药用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037837A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
CN104487587A (zh) * 2012-04-20 2015-04-01 新兴产品开发西雅图有限公司 Cd3结合多肽
CN106589129A (zh) * 2016-12-30 2017-04-26 上海近岸生物科技有限公司 一种结合cd19、cd3和cd28的三功能分子及其应用
CN106632681A (zh) * 2016-10-11 2017-05-10 北京东方百泰生物科技有限公司 抗egfr 和抗cd3双特异抗体及其应用
CN107922495A (zh) * 2015-07-31 2018-04-17 安进研发（慕尼黑）股份有限公司 结合egfrviii和cd3的双特异性抗体构建体
CN108290951A (zh) * 2015-09-23 2018-07-17 瑞泽恩制药公司 优化抗cd3双特异性抗体和其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
RU2547600C2 (ru) 2008-10-01 2015-04-10 Эмджен Рисерч (Мьюник) Гмбх Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
ES2889906T3 (es) * 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
EP3302555A4 (en) 2015-05-29 2018-07-11 Amphivena Therapeutics, Inc. Methods of using bispecific cd33 and cd3 binding proteins
CN107921130A (zh) * 2015-08-17 2018-04-17 宏观基因有限公司 能够结合b7‑h3和cd3的双特异性单价双抗体及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037837A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
CN104487587A (zh) * 2012-04-20 2015-04-01 新兴产品开发西雅图有限公司 Cd3结合多肽
CN107922495A (zh) * 2015-07-31 2018-04-17 安进研发（慕尼黑）股份有限公司 结合egfrviii和cd3的双特异性抗体构建体
CN108290951A (zh) * 2015-09-23 2018-07-17 瑞泽恩制药公司 优化抗cd3双特异性抗体和其用途
CN106632681A (zh) * 2016-10-11 2017-05-10 北京东方百泰生物科技有限公司 抗egfr 和抗cd3双特异抗体及其应用
CN106589129A (zh) * 2016-12-30 2017-04-26 上海近岸生物科技有限公司 一种结合cd19、cd3和cd28的三功能分子及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HANNAH R ROBINSON，等: "A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era", 《BLOOD》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023138551A1 (zh) * 2022-01-20 2023-07-27 上海君实生物医药科技股份有限公司 抗cd3和抗cd20双特异性抗体及其用途

Also Published As

Publication number Publication date
CN116396386A (zh) 2023-07-07
TW202021987A (zh) 2020-06-16
US20220242953A1 (en) 2022-08-04
CA3121565A1 (en) 2020-06-11
JP2022510322A (ja) 2022-01-26
BR112021010026A2 (pt) 2021-08-17
EP3892639A1 (en) 2021-10-13
KR20210100654A (ko) 2021-08-17
CN112955471B (zh) 2022-11-22
EP3892639A4 (en) 2022-08-24
ZA202104518B (en) 2023-01-25
MX2021006389A (es) 2021-07-15
AU2019394241A1 (en) 2021-06-03
WO2020114478A1 (zh) 2020-06-11
TWI821474B (zh) 2023-11-11
JP7461950B2 (ja) 2024-04-04

Similar Documents

Publication Publication Date Title
WO2020135201A1 (zh) 一种抗体及其用途
JP2022130393A (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
CN111417653A (zh) Cd47抗原结合分子
EP3936526A1 (en) Bifunctional fusion protein and pharmaceutical use thereof
CN112955471B (zh) Cd3抗体及其药物用途
WO2020114479A1 (zh) 多特异性蛋白分子
JP2021502407A (ja) ４−１ｂｂ抗体およびその製造方法と使用
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
WO2022068810A1 (zh) 抗Claudin18.2和CD3的双特异性抗体以及其用途
WO2021098822A1 (zh) 一种双特异性抗体
CN114206931A (zh) 抗pd-1抗体及其用途
WO2022105914A1 (zh) Cd70抗体及其应用
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
WO2022121941A1 (zh) 抗人msln的抗体及其用途
CN117083301A (zh) 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
RU2802272C2 (ru) Антитело к cd3 и его фармацевтическое применение
TWI837517B (zh) 抗claudin 18.2和cd3的雙特異性抗體以及其用途
WO2022171100A1 (zh) Gpc3人源化抗体及其应用
CN116848144A (zh) 抗pd-l1抗体及其用途
CA3231174A1 (en) Anti-cd79bxcd3 bispecific antibody and use thereof
CN116261590A (zh) 抗cd3抗体以及其用途
CN116997354A (zh) 用于诊断和治疗用途的针对lilrb1的单克隆抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051452

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant